- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Radiopharm Theranostics: Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
| Mo | RADIOPHARM THERANOSTICS LIMITED: Dr Oliver Sartor appointed to RAD Scientific Advisory Board | - | ASX | ||
| Mo | Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital | 1 | Investing.com | ||
| 16.07. | Radiopharm Theranostics erhält Steuergutschrift von 4,5 Millionen Dollar für F&E | 2 | Investing.com Deutsch | ||
| 16.07. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.07. | RADIOPHARM THERANOSTICS LIMITED: Radiopharm Receives $4.5M R&D Tax Incentive | - | ASX | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| 24.06. | Radiopharm unterzeichnet Liefervertrag mit Cyclotek für Prostatakrebs-Medikament | 1 | Investing.com Deutsch | ||
| 24.06. | Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for 6Tb-KLK3-mAb Phase I Clinical Trial in Australia | 108 | GlobeNewswire (Europe) | RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 ... ► Artikel lesen | |
| 24.06. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.06. | RADIOPHARM THERANOSTICS LIMITED: RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb | - | ASX | ||
| 11.06. | Radiopharm Gets FDA Fast Track Designation For RAD101, To Advance Phase 2 Clinical Trial; Stock Up | 3 | RTTNews | ||
| 11.06. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 04.06. | Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors | 98 | GlobeNewswire (Europe) | Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of 177Lu-RAD202 in individuals with advanced HER2-positive solid tumors Previous... ► Artikel lesen | |
| 02.06. | Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake | 170 | GlobeNewswire (Europe) | Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025... ► Artikel lesen | |
| 30.05. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.05. | Radiopharm Theranostics: ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 | 2 | GlobeNewswire (USA) | ||
| 12.05. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.05. | ThinkEquity initiates Radiopharm stock with Buy, $15 target | 1 | Investing.com | ||
| 12.05. | Hot Stocks: Ridley Corporation, Orthocell, Radiopharm | 3 | Finance News Network | ||
| 28.04. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,560 | +1,24 % | QIAGEN N.V.: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels | Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications... ► Artikel lesen | |
| EVOTEC | 6,230 | +0,48 % | Bayer, NetraMark, Evotec: Wie KI-Forschung jetzt Renditen beschleunigt und Ihr Depot optimieren könnte | Die Gesundheitsbranche wird 2025 von KI und Technologien radikal umgekrempelt. Während Pharmariesen unter Kostendruck und regulatorischen Stürmen ächzen revolutionieren Algorithmen die Arzneimittelentwicklung:... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,080 | 0,00 % | Aktien New York Schluss: Verluste - Sorgen um Krieg in Nahost nehmen zu | NEW YORK (dpa-AFX) - Die sich zuspitzende Lage in Nahost und die Unsicherheit über das weitere Vorgehen der USA haben am Dienstag die US-Börsen belastet. Der New Yorker Leitindex Dow Jones Industrial... ► Artikel lesen | |
| CG ONCOLOGY | 26,010 | 0,00 % | Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock | ||
| RECURSION PHARMACEUTICALS | 6,540 | 0,00 % | Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings | ||
| ARCUTIS BIOTHERAPEUTICS | 14,550 | +1,46 % | Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth | ||
| IMMUNOME | 11,070 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| BIONTECH | 94,90 | +0,21 % | BioNTech: Ryan Richardson verlässt Vorstand im Herbst | Bei BioNTech steht ein Wechsel im Vorstand bevor. Ryan Richardson wird seine Position als Chief Strategy Officer sowie seine Ämter in Tochtergesellschaften der BioNTech-Gruppe zum 30. September 2025... ► Artikel lesen | |
| PRIME MEDICINE | 4,530 | 0,00 % | JMP bestätigt Kursziel von 6 US-Dollar für Prime Medicine nach Finanzierung durch Mukoviszidose-Stiftung | ||
| RELAY THERAPEUTICS | 3,710 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
| POLYRIZON | 1,420 | 0,00 % | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| LENZ THERAPEUTICS | 32,980 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,445 | 0,00 % | Cogent Biosciences auf Rekordhoch: Positive Studienergebnisse und Kapitalerhöhung beflügeln Kurs | ||
| CRISPR THERAPEUTICS | 56,00 | -0,88 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| BEAM THERAPEUTICS | 21,540 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen |
Das Unternehmen RADIOPHARM THERANOSTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,130 (+3,02 %) liegt der Kurs bei 4,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.